Catalog No.
DHE07704
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
[VH-VH'-H-Gamma1-VL-VL'-C-kappa]-dimer
Clonality
Monoclonal
Target
IL13, NC30, Interleukin-13, IL-13, Binetrakin, B-cell stimulatory factor 1, Pitrakinra, Lymphocyte stimulatory factor 1, IL-4, BSF-1, IL4, Interleukin-4
Concentration
1.9 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P35225 & P05112
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, SAR156597, huTBTI3_2_1, CAS: 1399584-78-1
Clone ID
Romilkimab
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis, PMID: 32963047
An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years, PMID: 34074331
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date, PMID: 31916225
Molecular Features and Stages of Pulmonary Fibrosis Driven by Type 2 Inflammation., PMID:37369139
Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review., PMID:36837449
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications., PMID:34506339
An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years., PMID:34074331
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis., PMID:32963047
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date., PMID:31916225
For research use only. Not for human or drug use.
